Edition:
United States

Zogenix Inc (ZGNX.OQ)

ZGNX.OQ on NASDAQ Stock Exchange Global Market

43.45USD
23 Feb 2018
Change (% chg)

$0.25 (+0.58%)
Prev Close
$43.20
Open
$43.90
Day's High
$44.40
Day's Low
$42.95
Volume
94,341
Avg. Vol
196,439
52-wk High
$44.55
52-wk Low
$8.55

Latest Key Developments (Source: Significant Developments)

Zogenix Announces Receipt Of FDA Breakthrough Therapy Designation For ZX008
Tuesday, 6 Feb 2018 08:00am EST 

Feb 6 (Reuters) - Zogenix Inc ::ZOGENIX ANNOUNCES RECEIPT OF FDA BREAKTHROUGH THERAPY DESIGNATION FOR ZX008 IN DRAVET SYNDROME.ZOGENIX INC - FDA BREAKTHROUGH THERAPY DESIGNATION FOR ZX008 IS BASED ON RESULTS FROM STUDY 1.  Full Article

Zogenix Announces New Data From Pivotal Phase 3 Clinical Trial Of ZX008
Monday, 4 Dec 2017 08:00am EST 

Dec 4 (Reuters) - Zogenix Inc ::ZOGENIX ANNOUNCES NEW POSITIVE EFFICACY AND SAFETY DATA FROM PIVOTAL PHASE 3 CLINICAL TRIAL OF ZX008 IN DRAVET SYNDROME.ZOGENIX INC - DATA SHOWS ZX008 PATIENTS MORE LIKELY TO ACHIEVE CLINICALLY MEANINGFUL REDUCTION IN SEIZURE FREQUENCY COMPARED TO THOSE ON PLACEBO.ZOGENIX INC - LOOK FORWARD TO SHARING TOP-LINE RESULTS FROM SECOND PIVOTAL PHASE 3 TRIAL OF ZX008, STUDY 1504, IN Q2 OF 2018.  Full Article

Zogenix Announces Initiation Of Phase 3 Trial For ZX008 In Lennox-Gastaut Syndrome
Wednesday, 29 Nov 2017 08:05am EST 

Nov 29 (Reuters) - Zogenix Inc ::ZOGENIX ANNOUNCES INITIATION OF PHASE 3 TRIAL FOR ZX008 IN LENNOX-GASTAUT SYNDROME.  Full Article

Zogenix posts Q3 loss of $1.68 per share
Tuesday, 7 Nov 2017 04:01pm EST 

Nov 7 (Reuters) - Zogenix Inc :Zogenix provides corporate update and reports third quarter 2017 financial results.Q3 earnings per share view $-0.93 -- Thomson Reuters I/B/E/S.Q3 loss per share $1.68.At September 30, 2017, company had cash and cash equivalents of $64.7 million, compared to $91.6 million at December 31, 2016​.  Full Article

Zogenix prices public offering of common stock
Monday, 2 Oct 2017 08:05pm EDT 

Oct 2 (Reuters) - Zogenix Inc :Zogenix prices public offering of common stock.Priced an underwritten public offering of 6.7 million shares of its common stock at a price to public of $37.50 per share.  Full Article

Zogenix files for potential mixed shelf filing; size not disclosed - SEC filing‍​
Monday, 2 Oct 2017 06:59am EDT 

Oct 2 (Reuters) - Zogenix Inc :Files for potential mixed shelf filing; size not disclosed - SEC filing‍​.  Full Article

Zogenix announces proposed public offering of 4.3 mln shares
Monday, 2 Oct 2017 06:52am EDT 

Oct 2 (Reuters) - Zogenix Inc : :Zogenix announces proposed public offering of 4,300,000 shares of common stock.Zogenix Inc - ‍intends to use net proceeds from proposed offering to fund clinical research and development of zx008​.  Full Article

Zogenix announces positive phase 3 clinical trial of ZX008 in Dravet syndrome
Friday, 29 Sep 2017 07:00am EDT 

Sept 29 (Reuters) - Zogenix Inc : :Zogenix announces positive top-line results from pivotal phase 3 clinical trial of ZX008 in Dravet syndrome.Zogenix Inc - ZX008 also demonstrated statistical significance in all key secondary endpoints.Zogenix Inc - ‍primary endpoint was achieved.Zogenix Inc - ‍expect top-line results from second pivotal phase 3 trial, study 1504, which is nearing full enrollment, in first half of 2018​.Zogenix Inc - ‍ZX008 was generally well-tolerated in study.Zogenix Inc - remain on track to submit applications for regulatory approvals in U.S. And Europe in second half of 2018.  Full Article

Zogenix Q2 loss per share $0.93
Tuesday, 8 Aug 2017 04:01pm EDT 

Aug 8 (Reuters) - Zogenix Inc :Zogenix provides corporate update and reports second quarter 2017 financial results.Q2 loss per share $0.93.Q2 revenue $7.1 million.Q2 earnings per share view $-0.89 -- Thomson Reuters I/B/E/S.Q2 revenue view $3.5 million -- Thomson Reuters I/B/E/S.  Full Article

Zogenix and Durect Corp enter into termination agreement
Thursday, 3 Aug 2017 06:21am EDT 

Aug 3 (Reuters) - Zogenix Inc :Says on august 1, co and Durect Corporation entered into a termination agreement - sec filing.Agreement terminates the development and license agreement dated July 11, 2011, by and between company and Durect.Under Durect agreement, Durect granted to company worldwide development and commercialization rights to relday.  Full Article

BRIEF-Zogenix Completes Enrollment In Second ZX008 Phase 3 Clinical Trial In Dravet Syndrome

* ZOGENIX COMPLETES ENROLLMENT IN SECOND ZX008 PHASE 3 CLINICAL TRIAL IN DRAVET SYNDROME